ResearchMoz

Avastin (Breast Cancer) Analysis and Forecasts to 2020

GlobalData
Published Date » 2011-12-31
No. Of Pages » 47
   
 GlobalDatas pharmaceuticals report, Avastin (Breast Cancer)  Analysis and Forecasts to 2020 provides Avastin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 
   
 
  Scope...
Table of Contents

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 GlobalData Analysis and Estimates Report Guidance 7

3 Breast Cancer: Market Characterization 8
3.1 Breast Cancer Market 8
3.2 Breast Cancer Market Forecasts and CAGR 8
3.3 Drivers of Breast Cancer Market 9
3.3.1 High Prevalence 9
3.3.2 Breast Cancer: Most Frequent Cancer in Women 9
3.3.3 Increasing Breast Cancer Incidence Rate 10
3.3.4 Decreasing Breast Cancer Mortality Rate 11
3.3.5 High Survival Rates of Breast Cancer 14

4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15

5 Predictive Biomarker in the Treatment of Breast Cancer 18

6 Treatment Options of Breast Cancer 20

6.1 Stage 0 Breast Cancer: Treatment Options 20
6.2 Early Stage Breast Cancer (Excluding Stage 0) 21
6.3 Metastatic Breast Cancer (MBC) 23
6.3.1 Endocrine treatment: Adjuvant, First Line and Second Line 23
6.3.2 Cytotoxic Chemotherapy 25
6.3.3 Management of Patients with HER-2 Positive Patients 27

7 Avastin (bevacizumab) 29
7.1 Introduction 29
7.2 Mechanism of Action 29
7.3 Clinical Studies 29
7.4 Approval History of Avastin 30
7.5 Factors Affecting Sales of Avastin 31
7.5.1 Breast Cancer Market 31
7.5.2 Efficacy 31
7.5.3 Approval in Japan 31
7.5.4 Withdrawal of Approval in the US and Rejection in the UK 31
7.5.5 EMAs Verdict 31
7.6 Drug Evaluation 31
7.6.1 Drug Risk Benefit Score 31
7.6.2 Intensity of Competition 32
7.7 Sales Forecasts 32
7.7.1 Target Patient Pool of Avastin 33
7.7.2 Dosing 33
7.7.3 Market Penetration 34
7.7.4 Annual Cost of Therapy 34
7.7.5 Sales Projections of Avastin 34

8 Breast Cancer Market: Appendix 43
8.1 Market Definitions 43
8.2 Abberiviations 43
8.3 Research Methodology 43
8.3.1 Coverage 44
8.3.2 Secondary Research 44
8.3.3 Forecasting 44
8.3.4 Number of Patients Approved to take the Drug 44
8.3.5 Net Penetration of Drug 45
8.3.6 Net Annual Dosing 46
8.3.7 Annual Cost of Therapy 46
8.3.8 Primary Research 46
8.3.9 Expert Panels 46
8.4 Contact Us 47
8.5 Disclaimer 47
8.6 Sources 47

List of Tables


Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Table 3: Five-Year Relative Survival Rates, By Stages 14
Table 4: Phase III Clinical Study (E2100) Results for Avastin in Metastatic Breast Cancer 29
Table 5: Approval History of Avastin 30
Table 6: Drug Risk Benefit Score of Avastin 32
Table 7: Avastin, Breast Cancer, The US, The UK, France, Germany, Italy and Spain, Sales Estimates ($m), 20072010 35
Table 8: Avastin, Breast Cancer, France, Germany, Italy, Spain and Japan, Sales Forecasts ($m), 20072020 35
Table 9: Avastin, Breast Cancer, The US, Sales Estimates ($m) 20082010 36
Table 10: Avastin, Breast Cancer, The UK, Sales Estimates ($m) 20072010 37
Table 11: Avastin, Breast Cancer, France, Sales Forecasts ($m) 2007-2020 38
Table 12: Avastin, Breast Cancer, Germany, Sales Forecasts ($m) 20072020 39
Table 13: Avastin, Breast Cancer, Italy, Sales Forecasts ($m) 20072020 40
Table 14: Avastin, Breast Cancer, Spain, Sales Forecasts ($m) 20072020 41
Table 15: Avastin, Breast Cancer, Japan, Sales Forecasts ($m) 20112020 42

List of Figures


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 20102020 8
Figure 3: Top Ten Most Frequent Cancers on Incidence-Mortality Matrix, Worldwide, 2010 9
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 5: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 6: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 7: All Cancers, Incidence, Worldwide, 2008-2030 11
Figure 8: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 9: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 10: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 11: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 12: Broad Classification of Breast Cancer, By Type 15
Figure 13: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 14: Classification of Invasive Breast Cancer, By Stages 16
Figure 15: Classification of Invasive Breast Cancer, By Treatment 16
Figure 16: Classification of Metastatic or Advanced Breast Cancer 16
Figure 17: Classification of Early Stage Breast Cancer (Excluding Stage 0) 17
Figure 18: Classification of Locally Advanced Breast Cancer 17
Figure 19: Metastatic Breast Cancer Classification 17
Figure 20: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 18
Figure 21: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC 19
Figure 22: Breast Cancer Types in Decreasing Order of their Aggressiveness 19
Figure 23: Treatment Options, DCIS Breast Cancer 20
Figure 24: Treatment Options, LCIS Breast Cancer 21
Figure 25: Treatment Options, Stages I, II and IIIA 21
Figure 26: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 22
Figure 27: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 22
Figure 28: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 23
Figure 29: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 24
Figure 30: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 24
Figure 31: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 26
Figure 32: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 27
Figure 33: Drug Model Diagram of Avastin 33
Figure 34: Avastin, Breast Cancer, Global, Sales Forecasts ($m), 20072020 35
Figure 35: Avastin, Breast Cancer, The US, Sales Estimates ($m) 20082010 36
Figure 36: Avastin, Breast Cancer, The UK, Sales Estimates ($m) 20072010 37
Figure 37: Avastin, Breast Cancer, France, Sales Forecasts ($m) 2007-2020 38
Figure 38: Avastin, Breast Cancer, Germany, Sales Forecasts ($m) 20072020 39
Figure 39: Avastin, Breast Cancer, Italy, Sales Forecasts ($m) 20072020 40
Figure 40: Avastin, Breast Cancer, Spain, Sales Forecasts ($m) 20072020 41
Figure 41: Avastin, Breast Cancer, Japan, Sales Forecasts ($m) 20112020 42
Figure 42: Drug Model Diagram 45
Figure 43: Patients Approved for the Drug 46

Upcoming Reports:

Mineral Oil Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Mineral oil is a mixture of different alkanes obtained from petroleum distillation process. It is a colorless, transparent liquid and formed as a byproduct during petroleum distillation to manufacture petroleum based products. Mineral oil has applications in biomedicine, cosmetics, mechanical & industrial use as thermic fluid, food preparation and others.  Growing demand from cosmetics and food industry is expected to drive the mineral oil market. Owing to rising consumer demand from the growing young population and changing lifestyle is driving the cosmetics industry....
Hybrid Cars Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
The growing concern over the increasing carbon emissions has forced global automobile industry to develop advance and better vehicles running on alternative fuels. The factors such as Volatile Oil Prices, Shrinking of Fuel Reserves, Government Support and European Emission Standards are some of the factors driving the hybrid cars market. The report anticipates global hybrid automobile industry will witness a CAGR of more than 20 % over the period of 2012-2018. Government support will play a vital role in the growth of this industry.  This research report analyzes...
Molecular Biology Enzymes, Kits & Reagents Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Molecular biology enzymes, kits and reagents find their usage across a wide range of applications, such as, life science research, diagnostic testing and drug discovery, research and development. Molecular biology products are used for the analysis of cell surface markers that act as diagnostic and/or therapeutic targets. Polymerase chain reaction (PCR) that includes RT-PCR, qPCR, preparative PCR among others is one of the most commonly used diagnostic and preparative procedures in molecular biology. It can also be utilized in applications such as gene expression analysis, diagnostics...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Regulators Requesting a Broad Range of Communication Records
May 29, 2015  
Regulators are growingly requesting a broader range of communication records from organizations while conduction a regulatory test/exam. Email continues to be the most commonly requested record for communication; however, this trend is quickly changing. Around 77 percent of advisors state that the regulators have requested email data during a latest examination, states the...
Food and Wine Festival of Atlanta Makes a Grand Opening on 28th May
May 28, 2015  
A food festival, which has been nationally renowned, and has its headquarters at the Loews Atlanta Hotel in the Midtown, is all set to open on 28th of May. This event is expected to bring around thousands of people to this area in order to explore the authentic Southern beverage and food traditions. This will cover the entire region starting from Texas to Washington D.C.  Over the...
Beijing Invites to Taste Some of its Authentic Food Preparations
May 28, 2015  
The culinary profile of Beijing has been changed substantially over the last decade, which has given prime focus on the genuine culinary experiences and a bit less on the formal way of fine dining. According to Chief Executive Officer of the Rosewood Hotel Group, Sonia Cheng and also a native of Beijing stated that the direction that they are following currently is towards authentic, smaller,...
Where Does All the Food Go From Our Beloved Show Master Chef?
May 28, 2015  
Most of the countries enjoy the great food show held in Australia; however, most of the audience must be thinking about what the whole crew does with the remaining food every day. An answer to this turns out to be that, the whole fresh produce that the audience sees in the amazing jam-packed pantry is delivered to the SecondBite, which is a charity that makes provisions to provide nutritious...
New Trend Ushered in Europe to See Funds Firms Become Bank in All Respect But the Name
May 28, 2015  
According to analysts, Symon Drake-Brockman hailing from Australia is on the forefront of the revolution which is about to take the European finance industry by storm. The former head honcho in the debt markets department at Royal Bank of Scotland, Symon Drake-Brockman has now taken over the realms of Pemberton Asset Management located at the genteel community of Belgravia in London. ...